Background: Several French, Belgian and Dutch radiation oncologists have reported good results with the combination of limited surgery after external beam radiotherapy (EBRT) followed by brachytherapy in early-stage muscle-invasive bladder cancer.
introduction
Bladder cancer is a very frequent tumor type, ranking in the top 10 cancers of the Western world [1, 2] . The role of radiotherapy as part of the treatment for patients with bladder cancer is modest [3] . Patients with superficial tumors are treated with transurethral resection of the tumor (TURT) and instillation of, for example, Bacillus Calmette-Guérin (BCG) or mitomycin C, depending on multifocality, tumor grade and recurrence pattern. Muscle-invasive cancers are treated with cystectomy, which yields considerable morbidity and mortality. In spite of the improved possibilities of neobladder construction, the loss of one's own bladder function can be considered a major type of mutilation [4] [5] [6] [7] . Radiochemotherapy can be offered to selected groups of patients, resulting in improved local control [8] [9] [10] . External beam radiotherapy (EBRT) is an alternative treatment with reasonably good results for those who are too frail to undergo cystectomy or for those who refuse major surgery [11, 12] .
For a well-defined group of patients, brachytherapy combined with limited surgery and EBRT offers a bladdersaving approach. Inclusion criteria are: stage pT1-T3, cN0 or pN0, cM0, unifocal carcinoma and size ≤5 cm diameter. The tumor located in the bladder neck is a relative contra-indication for implantation as this area is not easily accessible for implant materials. This technique was first described by Breur et al. in 1956 and propagated by Van der Werf-Messing in the 1970s and 1980s [13] [14] [15] . About half of the radiation oncology departments in the Netherlands and a few centers in France and Belgium followed this technique [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] . The reports showed local control rates between 73% and 89% at 5 years.
brachytherapy technique
Brachytherapy is a radiotherapy modality in which single or multiple radioactive sources are positioned in or close to a tumor. This is accomplished by either manual or remote afterloading. First, an applicator consisting of one or more flexible catheters, rigid needles or hollow tubes is inserted into the patient during surgery. Secondly, radioactive sources are introduced with forceps into the applicator or the applicator is connected to an afterloader, which is capable of transporting the radioactive source(s) into the applicator under computer control.
Three generally applied techniques can be distinguished, i.e. continuous low-dose rate (CLDR), pulsed dose rate (PDR) and high dose rate (HDR) techniques, respectively. In the CLDR, multiple sources are inserted which stay in position, in or near the tumor, during the complete time span of treatment, which can vary from a few hours to a few days, depending on the dose to be delivered to the patient. In the PDR or HDR, one highly active single source moves stepwise through the volume of tissue to be irradiated. This technique offers the possibility of conforming the three-dimensional dose distribution to the tumor, which is difficult to perform with the CLDR. In the PDR, the total dose is delivered in multiple fractions ( pulses) with typically 1-2 h in between pulses, with an overall treatment time comparable with the CLDR. In the HDR, the dose is delivered in one single or only a few fractions, generally in a shorter overall treatment time. In practice, the choice for PDR is often based on the radiobiological resemblance with the CLDR. The choice for the HDR is often based on logistical advantages of few treatment fractions and economical use of treatment machines.
For brachytherapy of bladder cancer, the applicator usually consists of two to four flexible catheters, inserted after partial cystectomy or cystotomy.
To bridge the gaps between the opinions of urologists and radiation oncologists worldwide about the merits of a bladderpreserving approach by using brachytherapy, data on treatment and outcomes were retrospectively collected in a Dutch multicenter database. The results of the analyses of these data are presented in this paper.
methods
All 13 Dutch radiation oncology departments offering bladder-saving treatment, including brachytherapy, were invited to send their data on patients treated, treatment given, results and toxicities. Twelve departments responded. In total, data on 1040 patients were collected; the contribution varied from 6 to 176 per center with an average of 87 patients.
Patients were treated with TURT, EBRT, suprapubic cystotomy or partial cystectomy followed immediately by the placement of catheters for brachytherapy.
patients
Between 1983 and 2010, 1040 patients were treated, 229 females and 811 males with a median age of 66 years, range 28-92 years. The age limits and median age did not differ between the institutes.
Tumors were well differentiated in 13 (1.3%) patients, moderately differentiated in 167 (16%) patients and poorly differentiated in 824 (79%) patients; undifferentiated in 16 (1.5%) patients; and unknown for 20 (1.9%) patients. The most frequent histology was transitional cell carcinoma 863 (83%), followed by 114 cases (11%) papillary transitional cell carcinoma and 37 (3.6%) adenocarcinomas. Tumor diameter was ≤3 cm in 725 (70%) patients, >3 and ≤5 cm in 224 (22%) patients. In 10 (1%) cases, the diameter was >5 cm and unknown for 61 (5.9%) patients. There were 126 (12%) pT1 tumors, 797 (77%) pT2 tumors, 100 (9.5%) pT3 tumors and 2 pT0, 1 pTA, 4 pT4 and 10 pTx tumors.
treatment surgery
Patients underwent a suprapubic cystotomy in 791 (76%) cases or a partial cystectomy in 247 (24%) cases followed by catheter implant for brachytherapy. In general, patients with a tumor located in the bladder dome or a diverticle or with an invasion depth >10 mm underwent partial cystectomy. Lymphadenectomy was not performed on a routine basis.
EBRT and brachytherapy: administered dose
All patients started with EBRT. The EBRT dose varied from 10 to 55 Gy. The brachytherapy dose varied mainly between 25-40 and 50-60 Gy.
A lower EBRT dose (10 Gy) was mainly combined with a higher brachytherapy dose (50-60 Gy). A low dose EBRT, usually 3 × 3.5 Gy, was prescribed to prevent implantation of tumor cells in the wound area during surgery.
Two institutes had the following strategy: for low-grade and/or low-stage tumors (pT1 G1-3, pT2 G1-2 and ≤3 cm) treatment was mainly high-dose brachytherapy. High-grade and high-stage tumors (pT1 G3 and >3 cm, pT2 G1-2 and >3 cm, pT2 G3 and small pT3) were treated with 40 Gy EBRT to the pelvis followed by a brachytherapy boost of 25-40 Gy. Two institutes applied a low EBRT dose to almost all patients, followed by high brachytherapy dose. The other seven departments used high-dose EBRT followed by low-dose brachytherapy. One institute treated six patients only and their data were not analyzed. In general, the combined total physical dose was ∼70 Gy.
Patients in this study underwent treatment with the CLDR (819 patients) or with the PDR (184 patients); 17 patients were treated with the HDR. In 20 cases, the exact brachytherapy data were missing. The brachytherapy applied according to patient and tumor characteristics and dose data are presented in Table 1 and supplementary Table S1 . More details about applied doses, dose rate and overall treatment times can be found in a number of separately published studies [16, [19] [20] [21] [22] .
statistical analysis
Survival data were calculated from the initial date of EBRT. The actuarial survival curves were constructed according to the Kaplan-Meier method. The influence of age, histological grade, pT stage, tumor diameter, participating department and brachytherapy technique was analyzed using univariate and multivariate Cox regression analyses, using the Breslow 
follow-up
The follow-up period varied from a minimum of 0 to a maximum of 311 months with a mean of 65 months and a median of 50 months. The first cystoscopy was performed 3 months after brachytherapy and with a 3-month interval during the first 2 years. Between 3 and 5 years of follow-up, cystoscopies were done every half year. After 5 years, a cystoscopy was performed once a year. The local recurrence was defined as any tumor growth in the bladder either superficial, infiltrating or both.
results
The local recurrence-free probability was 91% at 1 year (95% confidence interval (CI) 89%-93%), 80% at 3 years (CI 77%-83%) and 75% at 5 years (CI 72%-78%) (fig 1) . The metastasisfree probability was 91% at 1 year (CI 90%-93%), 80% at 3 years (CI 77%-82%) and 74% at 5 years (CI 71%-77%) (supplementary fig. S1 , available at Annals of Oncology online). The 1-, 3-and 5-year disease-free probability was 85% (CI 83%-87%), 68% (CI 65%-71%) and 61% (CI 58%-65%), respectively (supplementary fig. S2 , available at Annals of Oncology online). The overall survival probability was 91% at 1 year (CI 90%-93%), 74% at 3 years (CI 71%-77%), 62% at 5 years (CI 59%-66%) and 44% at 10 years (CI 41%-48%) (fig 2) . At 5 years, there were 136 (13%) patients with local recurrences only, 145 (14%) patients with distant metastases only and 94 (9%) patients with both local recurrence and distant metastases; of 2 patients, the site of recurrence was unknown.
For 11 of 12 departments, the local control results are presented in figure 3 . Those with the best and with the poorest outcome are highlighted. One department treated only six patients between 2001 and 2007 and stopped after experiencing poor results. Univariate analysis shows that age, histological grade and internal dose were associated with overall survival. After multivariate analysis, age, grade and tumor diameter were significant factors, P < 0.001, P = 0.02 and P = 0.02, respectively, ( Table 2) . Brachytherapy technique (PDR versus CLDR) and nodal stage were significant factors for local control in the uniand multivariate analyses ( Table 2 ). Due to the small number of patients treated with the HDR, this technique was not taken into account for this analysis, nor the patients with unknown brachytherapy technique.
Grade and tumor diameter were of significant influence on distant metastases in uni-and multivariate analyses, P = 0.04 and P < 0.001 and P = 0.05 and P < 0.01, respectively (Table 2) .
No significant difference could be observed in freedom from local recurrence between institutes treating a smaller number of patients (<100) compared with the ones with a larger number (≥100 patients), P = 0.32.
Of the 232 relapses in the bladder, 51 were invasive, 94 were superficial, 31 were both invasive and superficial and 56 were unknown (see supplementary Table S2 ). For the local recurrences, 62 (6% of all 1040 patients) underwent cystectomy, 110 (10.5%) patients received a different treatment, such as TURT and instillations. For 60 patients, the subsequent treatment was unknown.
Late toxicity was assessed: 24 patients developed a fistula, 144 patients a type of necrosis or ulceration and in 93 patients other types were reported without further requested specification. One center reported 77 ulcerations in 176 treated patients (see supplementary Table S2 ). The multivariate analysis shows that age and external dose are significant factors, P = 0.03 and 0.04, respectively ( Table 2 ). The toxicity incidence probability is presented in supplementary fig. S3 , available at Annals of Oncology online.
discussion
Brachytherapy combined with EBRT and cystotomy or partial cystectomy offers robust results in terms of local control for well-defined subgroups of patients with bladder cancer. The present report adds to the evidence by providing the results of a multicenter survey, presenting the largest group of patients treated with this approach reported thus far. Although the choice between high EBRT dose followed by low-dose brachytherapy and vice versa differs between the participating departments, this does not affect the treatment outcome. The differences between the contributing departments are small and can be explained by variations in brachytherapy technique, e.g. the use of PDR versus CLDR.
The treatment is a joint effort of urologists who perform the TURTs, instillations, cystotomy, partial cystectomy and followup cystoscopies and radiation oncologists who insert the brachytherapy catheters and define the optimal dose delivery. Close cooperation is therefore mandatory.
The Dutch results are comparable with those of Rozan et al. who reported local control in the same range in a French Figure 3 . Local recurrence-free probability.
Annals of Oncology original articles multicenter survey [24] . Of their local recurrences, 13 (6.5%) of 205 patients underwent salvage cystectomy, which is completely comparable with our data (6%). The distant metastasis-free 5-year survival in our series is 75% and the disease-free survival at 5 years is 61%, while the overall 5-and 10-year survival is 62% and 44%, respectively. In general, old patients were not excluded. Although age, grade and tumor diameter were significant factors for survival probability, age was the most statistically significant factor for survival. This reflects the relatively high age of this group of patients, who are at high risk to die due to other causes.
Visser et al. reported 5-year overall survival rates of 80% for stage I, 44% for stage II and 28% for stage III after cystectomy with local recurrence rates of 11% for stage I and II and 23% for stage III [1] . The results for cystectomy and bladderconserving therapy thus seem to be highly comparable. Prospective randomized controlled studies, however, have never been performed and several authors doubt whether this will ever happen [3, 16, 21, 22] . Recently, two studies addressed the question of which approach should be preferred [19, 21] . Their conclusions were that brachytherapy not only spared bladders but also produced similar local control and survival results. With long-time follow-up, patients with a preserved bladder are at risk for late bladder recurrences which will in general be new primary tumors. Smoking and aniline are known to be toxic for the bladder mucosa and these influences usually cannot be switched off.
Brachytherapy with its sharp dose drop-off offers a radiobiologically high radiation dose to the tumor area while sparing the rest of the bladder wall and organs in the close neighborhood, such as the small intestine. The PDR appears superior to the CLDR treatment. Moreover, the former-more recently introduced-modality allows interruptions between pulses during which the patient can be nursed and visited. Because PDR is a stepping source technology offering 3D dose optimization, the improvement might be due to this aspect rather than just the use of PDR itself. HDR brachytherapy was seldom applied. Pos et al. reported inferior results in terms of tumor control and a higher complication rate. Their specific results are excluded from our collected data since they have been reported separately [26] . The conclusion is that HDR is not the way to perform safe brachytherapy for bladder cancer.
Several details about acute and late toxicities are missing in this collective report due to its retrospective character. Most of them can be found in separate articles [16, 19, 20, 22, 24] . The main conclusions of those articles agree obviously with this current paper. In general, side-effects are limited in frequency and severity. The two factors related to toxicity, age and EBRT dose, are statistically significant but not clinically relevant, see coefficient values in Table 2 . Pernot et al. reported four patients with a grade 3 and one with a grade 4 late toxic effects out of a total of 85 patients. These side-effects were-among others-related to the strength of the radioactive wires. Rozan et al. reported one cystectomy for a late complication in 205 patients treated in eight French centers [24] . In total, 29 patients developed more serious complications related to the partial cystectomy, the activity of the sources and maybe the EBRT dose. In the article by Blank et al., 5% of the patients had urinary function deterioration ending in a crippled bladder in three [16] . One of these three patients underwent cystectomy. Bladder function was assessed in about half of the patients in their series and bladder capacity, voiding frequency and nocturia were reported for different numbers of patients. In 6 out of 55 patients, the capacity decreased, in 7 of 47 patients the frequency increased as did the nocturia in 19 of 74 patients, respectively.
In one of the participating departments, 77 of the 176 patients were reported to develop local bladder ulceration or necrosis. Their total dose of EBRT and brachytherapy was higher than in the other departments. Ulceration can be observed, causes no complaints in most patients and usually disappears with time: within a few months after ulcerations are observed around half a year after treatment, they are cured [23, 27] .
In conclusion, within the limitations of the retrospective setup of this data collection and analyses, this nationwide study confirms that a bladder-sparing approach including limited local surgery, EBRT and brachytherapy can be offered safely to selected groups of patients. Therefore, more patients worldwide should be offered this bladder-preserving treatment, providing comparable results with those obtained by cystectomy in terms of local control, metastasis-free and overall survival. 
